Table 1.
GWAS meta-analysis result summary for loci with p<5×10−8
| Phenotype | CHR:POS | SNP | EA | NEA | EAF | OR (95% CI) | p value | Dir | N (studies) | Genes |
|---|---|---|---|---|---|---|---|---|---|---|
| Novel locus | ||||||||||
| CKD+DKD | 5:166978230 | rs72831309 | A | G | 0.039 | 2.08 (1.62, 2.67) | 9.8×10−9 | +++ | 8570 (7) | TENM2a,b |
| Previous loci | ||||||||||
| CKD | 2:3745215 | rs12615970 | A | G | 0.867 | 1.31 (1.20, 1.44) | 9.4×10−9 | +?? | 18,488 (13) | ALLCb, COLEC11 |
| All vs Ctrl | 2:228121101 | rs55703767 | T | G | 0.207 | 0.86 (0.82, 0.90) | 1.9×10−9c | −+− | 26,898 (24) | COL4A3a,b |
| CKD+DKD | 2:228121101 | rs55703767 | T | G | 0.210 | 0.81 (0.75, 0.88) | 4.7×10−8 | −+− | 17,611 (17) | COL4A3a,b |
| Severe DKD | 2:228121101 | rs55703767 | T | G | 0.208 | 0.82 (0.77, 0.87) | 3.6×10−11c | −−− | 21,898 (23) | COL4A3a,b |
| ESRD | 3:926345 | rs115061173 | A | T | 0.014 | 9.40 (4.22, 20.93) | 4.1×10−8 | +?? | 4827 (3) | LINC01266b, CNTN6a |
| Micro | 3:11910635 | rs142823282 | A | G | 0.983 | 0.15 (0.08, 0.27) | 8.3×10−10c | −?? | 6076 (2) | TAMM41 |
| ESRD vs all | 3:36566312 | rs116216059 | A | C | 0.016 | 8.73 (4.13, 18.45) | 1.4×10−8 | +?? | 3667 (2) | STACb, DCLK3 |
| Severe DKD | 4:71358776 | rs191449639 | A | T | 0.005 | 32.42 (9.77, 107.59) | 1.3×10−8 | +?? | 7768 (2) | MUC7, AMTN |
| Micro | 7:99728546 | rs77273076 | T | C | 0.008 | 9.16 (4.29, 19.56) | 1.1×10−8 | +?? | 7500 (2) | MBLAC1, ZNF3 |
| ESRD vs macro | 8:128100029 | rs551191707 | CA | C | 0.122 | 1.69 (1.40, 2.04) | 4.4×10−8 | +?? | 3634 (7) | PRNCR1b |
| Micro | 11:16937846 | rs183937294 | T | G | 0.993 | 0.06 (0.02, 0.16) | 1.7×10−8 | −?? | 6076 (2) | PLEKHA7a,b |
| CKD | 18:1811108 | rs185299109 | T | C | 0.007 | 20.75 (7.30, 59.00) | 1.3×10−8 | +?? | 7223 (2) | LINC00470 |
aGene prioritised by PoPS
bGenes underlying the lead SNP
cp<9.3×10−9 (i.e. corrected for 5.36 effective tests [phenotypes])
CHR:POS, variant chromosome and basepair position; Ctrl, control; Dir, direction of association in DNCRI (type 1 diabetes), SUMMIT-2 (type 2 diabetes) and in SUMMIT-1 (type 1 diabetes), respectively; EA, effect allele; EAF, effect allele frequency; Genes, closest gene(s); Micro, microalbuminuria vs normal AER; NEA, non-effect allele; N (studies), number of contributing individuals and studies